Valneva Reports H1 2019 Results Marked by Strong Operational Performance and Major Corporate Progress

Valneva regains control of key R&D assets, strengthens financial outlook with $23 million CEPI chikungunya grant

Strong product sales and financial performance in H1 2019

Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, reported today its consolidated financial results for the first half of the year, ended June 30, 2019. The half year financial report, including the condensed consolidated interim financial report and the half year management report, is available on the Company’s website

Read more